NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation

NFL Biosciences Releases New Results on NFL-101 and Reaffirms Its Personalized Approach to Smoking Cessation

Identification of a biomarker predictive of efficacy, enabling a personalized approach to smoking cessation with NFL-101

In the target population, efficacy approximately 30% higher than that of Champix® (based on results from the EAGLES study)

Target population carrying the biomarker represents 57% of patients, opening significant market potential

Statistically significant results versus placebo, confirming the clinical potential of NFL-101 in the target population